A5087138210- Asthma and respiratory diseases
- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- Allergic Rhinitis and Sensitization
- Chronic Obstructive Pulmonary Disease (COPD) Research
- IL-33, ST2, and ILC Pathways
- Respiratory and Cough-Related Research
- Food Allergy and Anaphylaxis Research
- Respiratory viral infections research
- Pharmaceutical studies and practices
- Pediatric health and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research
- Vitamin D Research Studies
- Immune Cell Function and Interaction
- Dermatology and Skin Diseases
- Case Reports on Hematomas
- Bacterial Genetics and Biotechnology
- Radiopharmaceutical Chemistry and Applications
- Gastroesophageal reflux and treatments
- Fungal and yeast genetics research
- Transgenic Plants and Applications
- Contact Dermatitis and Allergies
- Respiratory Support and Mechanisms
- Autoimmune and Inflammatory Disorders
Regeneron (United States)
2023-2025
Cincinnati Children's Hospital Medical Center
2016-2023
University of Cincinnati
2017-2023
University of Cincinnati Medical Center
2020-2022
Oncology Hematology Care
2016
University of Wisconsin–Madison
2011-2013
University of Colorado Denver
2010-2012
UW Health University Hospital
2012
University of Colorado Health
2010
Denver Health Medical Center
2010
Eosinophilic gastritis and duodenitis are characterized by gastrointestinal mucosal eosinophilia, chronic symptoms, impaired quality of life, a lack adequate treatments. Mast-cell activity may contribute to the pathogenesis conditions. AK002 (lirentelimab) is an anti-Siglec-8 antibody that depletes eosinophils inhibits mast cells has shown potential in animal models as treatment for eosinophilic duodenitis.In this phase 2 trial, we randomly assigned adults who had symptomatic gastritis,...
<h3>Importance</h3> Severe asthma exacerbations cause significant morbidity and costs. Whether vitamin D<sub>3</sub>supplementation reduces severe childhood is unclear. <h3>Objective</h3> To determine whether improves the time to a exacerbation in children with low D levels. <h3>Design, Setting, Participants</h3> The Vitamin Prevent Asthma Exacerbations (VDKA) Study was randomized, double-blind, placebo-controlled clinical trial of improve high-risk aged 6 16 years taking low-dose inhaled...
Dupilumab has shown long-term treatment benefits in children with uncontrolled asthma. We assessed more detail the impact of dupilumab on asthma control and health-related quality life (HRQoL) their caregivers.Children aged 6-11 years moderate-to-severe type 2 (baseline blood eosinophils ≥150 cells·µL-1 or fractional exhaled nitric oxide ≥20 ppb; n=350) were treated placebo for 52 weeks VOYAGE study. Primary outcomes these analyses (change from baseline Asthma Control Questionnaire 7...
Background Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved the treatment of EoE in patients ≥ 1 year old, weighing 15 kg. This analysis aimed to evaluate dupilumab from LIBERTY TREET trial (NCT03633617), with prior history different interventions.
Exposure to violence has been associated with lower lung function in cross-sectional studies.We examined whether increasing violence-related distress over time is worse and asthma control or quality of life a secondary analysis 48-week randomised clinical trial 98 youth (aged 9-16 years) treated low-dose inhaled corticosteroids (Vitamin D Kids Asthma Study (VDKA)). We then replicated our findings for prospective study 232 Puerto Rican followed an average 5.4 years. Violence-related was...
Scope: Ara h 6 has recently been recognized as an important peanut allergen. Recombinant allergens have used for analysis of IgE binding, but not to analyze the allergic effector activity that is more relevant reactions. Methods and results: was expressed a recombinant protein in both E scherichia coli Pichia pastoris (rAra 6‐ E. rAra , respectively). Effector assayed by measuring degranulation RBL SX‐38 cells sensitized with from patients severe allergy. Compared native (nAra 6), had intact...
<ns4:p>Eosinophilic esophagitis is a chronic, antigen-driven, eosinophil-predominant inflammatory disease of the esophagus and affects both children adults. Cutting-edge technologies, such as genome-wide association studies, have advanced our understanding pathogenesis at remarkable rate. Recent insights from genetic mechanistic studies concluded that complex interplay between environmental risk factors, allergic sensitization, esophageal-specific pathways leads to pathogenesis. Importantly,...
Abstract Background Dysphagia is the predominant symptom of EoE in adolescents and adults. Aims To assess change number days with dysphagia, action taken to relieve pain associated dysphagia patients receiving dupilumab 300 mg once weekly (qw) vs placebo LIBERTY TREET. Methods Symptom Questionnaire (DSQ) score (range 0–84) was calculated from daily responses over 14 for Q2 (frequency) Q3 (severity); Q4 (pain) separately assessed 0–56). Higher scores indicate a worse outcome. Inclusion...
Abstract Background Improvements in histologic, symptomatic, and endoscopic aspects of eosinophilic oesophagitis (EoE) were observed patients treated with dupilumab weekly (qw) enrolled the 3-part, phase 3 LIBERTY EoE TREET study (NCT03633617), regardless prior inadequate response, intolerance, and/or contraindication to swallowed topical corticosteroids (STC). Here we assess efficacy qw versus placebo this STC non-responsive/intolerant subgroup, stratifying further by those with/without...